Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (311-320 of 999) with videos related to

Pageof 100
Sort By:
Cardiovascular Drugs and Therapy|May 31, 2021
Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-AnalysisXiaoming Jia, Feng Gao, June K Pickett, et al.
The American Journal of Cardiology|July 24, 2012
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Christie M Ballantyne, Harold E Bays, John J Kastelein, et al.
Journal of Clinical Lipidology|June 9, 2026
Correlation between serum and plasma lipoprotein(a) measurements: ARIC studyYakubu Bene-Alhasan, Caroline Sun, Arsalan Hamid, et al.
Diabetes Care|February 22, 2011
Nontraditional markers of glycemia: associations with microvascular conditionsElizabeth Selvin, Lesley M A Francis, Christie M Ballantyne, et al.
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
Hypertension (Dallas, Tex. : 1979)|July 8, 2015
Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities StudyMichael D Miedema, Faye L Lopez, Michael J Blaha, et al.
Circulation|June 19, 2015
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) StudyAaron R Folsom, Lu Yao, Alvaro Alonso, et al.
Journal of the American Heart Association|October 26, 2022
Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities StudyMatthew R Deshotels, Caroline Sun, Vijay Nambi, et al.
The American Journal of Cardiology|March 4, 2008
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statinsEvan A Stein, Christie M Ballantyne, Eberhard Windler, et al.
Diabetology & Metabolic Syndrome|June 29, 2013
Chronic inflammation role in the obesity-diabetes association: a case-cohort studyVivian C Luft, Maria I Schmidt, James S Pankow, et al.
Pageof 100

Showing results (311-320 of 999) with videos related to

Sort By:
Pageof 100
Cardiovascular Drugs and Therapy|May 31, 2021
Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-AnalysisXiaoming Jia, Feng Gao, June K Pickett, et al.
The American Journal of Cardiology|July 24, 2012
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Christie M Ballantyne, Harold E Bays, John J Kastelein, et al.
Journal of Clinical Lipidology|June 9, 2026
Correlation between serum and plasma lipoprotein(a) measurements: ARIC studyYakubu Bene-Alhasan, Caroline Sun, Arsalan Hamid, et al.
Diabetes Care|February 22, 2011
Nontraditional markers of glycemia: associations with microvascular conditionsElizabeth Selvin, Lesley M A Francis, Christie M Ballantyne, et al.
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
Hypertension (Dallas, Tex. : 1979)|July 8, 2015
Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities StudyMichael D Miedema, Faye L Lopez, Michael J Blaha, et al.
Circulation|June 19, 2015
Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) StudyAaron R Folsom, Lu Yao, Alvaro Alonso, et al.
Journal of the American Heart Association|October 26, 2022
Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities StudyMatthew R Deshotels, Caroline Sun, Vijay Nambi, et al.
The American Journal of Cardiology|March 4, 2008
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statinsEvan A Stein, Christie M Ballantyne, Eberhard Windler, et al.
Diabetology & Metabolic Syndrome|June 29, 2013
Chronic inflammation role in the obesity-diabetes association: a case-cohort studyVivian C Luft, Maria I Schmidt, James S Pankow, et al.
Pageof 100